世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ライム病診断薬市場(診断テスト:診断テスト:血清学的テスト、ポリメラーゼ連鎖反応[PCR]テスト、その他;およびサンプル:世界の産業分析、市場規模、シェア、成長、動向、予測、2023-2031年


Lyme Disease Diagnostics Market (Diagnostic Test: Serological Test, Polymerase Chain Reaction [PCR] Test, and Others; and Sample: Blood, Cerebrospinal Fluid [CSF], and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

ライム病診断薬市場 - レポートの範囲 TMRの調査レポート「世界のライム病診断薬市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Transparency Market Research
トランスペアレンシーマーケットリサーチ
2023年8月8日 US$5,795
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
180 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

ライム病診断薬市場 - レポートの範囲
TMRの調査レポート「世界のライム病診断薬市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界のライム病診断薬市場の収益を提供しています。また、2023年から2031年までの世界のライム病診断薬市場の複合年間成長率(CAGR %)も掲載しています。

本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、ライム病診断薬市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書を参照した。

二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれます。アナリストは、世界のライム病診断薬市場の様々な属性を調査するために、トップダウンアプローチとボトムアップアプローチの組み合わせを採用しました。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界のライム病診断薬市場における競争ダイナミクスの変化に光を投げかけています。これらは、既存の市場プレイヤーだけでなく、世界のライム病診断薬市場への参入に関心のある企業にとっても貴重なツールとなります。

本レポートでは、世界のライム病診断薬市場の競争環境について掘り下げています。世界のライム病診断薬市場で事業を展開する主要企業が特定され、これらの各企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界のライム病診断薬市場におけるプレイヤーの属性である。

世界のライム病診断薬市場レポートで回答された主な質問
- 予測期間中の全地域におけるライム病診断薬の売上高/収益は?
- 世界のライム病診断薬市場におけるビジネスチャンスは?
- 市場における主な促進要因、阻害要因、機会、脅威は何か?
- 予測期間中に最も速いCAGRで拡大する地域市場はどこか?
- 2031年に世界で最も高い収益を上げると予測されるセグメントは?
- 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは?
- 世界市場で事業を展開する各企業の市場ポジションは?

ライム病診断薬市場 - 調査目的と調査アプローチ
ライム病診断薬の世界市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと流通業者、製品の承認に関する規制シナリオについて詳細に説明しています。

本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴える。また、過去と予測期間末の主要セグメントの市場シェアを比較することもできる。

本レポートでは、世界のライム病診断薬市場を製品、エンドユーザー、地域の観点から分析している。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界のライム病診断薬市場への投資について、情報に基づいたビジネス上の意思決定を行うことが可能となります。

ページTOPに戻る


目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lyme Disease Diagnostics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Lyme Disease Diagnostics Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projection (US$ Mn)
5. Key Insights
    5.1. Innovations in Diagnostic Testing for Lyme disease
    5.2. Incidence and Prevalence of Lyme Disease
    5.3. Regulatory Scenario by Region/Globally
    5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact)
6. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Diagnostic Test
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Diagnostic Test, 2017-2031
        6.3.1. Serological Test
            6.3.1.1. ELISA
            6.3.1.2. Western Blot
        6.3.2. Polymerase Chain Reaction (PCR) test
        6.3.3. Others
    6.4. Market Attractiveness Analysis, by Diagnostic Test
7. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Sample
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Sample, 2017-2031
        7.3.1. Blood
        7.3.2. Cerebrospinal Fluid (CSF)
        7.3.3. Others
    7.4. Market Attractiveness Analysis, by Sample
8. Global Lyme Disease Diagnostics Market Analysis and Forecast, by End-user
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by End-user, 2017-2031
        8.3.1. Hospitals
        8.3.2. Diagnostic Laboratories
        8.3.3. Others
    8.4. Market Attractiveness Analysis, by End-user
9. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2017-2031
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Lyme Disease Diagnostics Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Diagnostic Test, 2017-2031
        10.2.1. Serological Test
            10.2.1.1. ELISA
            10.2.1.2. Western Blot
        10.2.2. Polymerase Chain Reaction (PCR) test
        10.2.3. Others
    10.3. Market Value Forecast, by Sample, 2017-2031
        10.3.1. Blood
        10.3.2. Cerebrospinal Fluid (CSF)
        10.3.3. Others
    10.4. Market Value Forecast, by End-user, 2017-2031
        10.4.1. Hospitals
        10.4.2. Diagnostic Laboratories
        10.4.3. Others
    10.5. Market Value Forecast, by Country, 2017-2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Diagnostic Test
        10.6.2. By Sample
        10.6.3. By End-user
        10.6.4. By Country
11. Europe Lyme Disease Diagnostics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Diagnostic Test, 2017-2031
        11.2.1. Serological Test
            11.2.1.1. ELISA
            11.2.1.2. Western Blot
        11.2.2. Polymerase Chain Reaction (PCR) test
        11.2.3. Others
    11.3. Market Value Forecast, by Sample, 2017-2031
        11.3.1. Blood
        11.3.2. Cerebrospinal Fluid (CSF)
        11.3.3. Others
    11.4. Market Value Forecast, by End-user, 2017-2031
        11.4.1. Hospitals
        11.4.2. Diagnostic Laboratories
        11.4.3. Others
    11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Diagnostic Test
        11.6.2. By Sample
        11.6.3. By End-user
        11.6.4. By Country/Sub-region
12. Asia Pacific Lyme Disease Diagnostics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Diagnostic Test, 2017-2031
        12.2.1. Serological Test
            12.2.1.1. ELISA
            12.2.1.2. Western Blot
        12.2.2. Polymerase Chain Reaction (PCR) test
        12.2.3. Others
    12.3. Market Value Forecast, by Sample, 2017-2031
        12.3.1. Blood
        12.3.2. Cerebrospinal Fluid (CSF)
        12.3.3. Others
    12.4. Market Value Forecast, by End-user, 2017-2031
        12.4.1. Hospitals
        12.4.2. Diagnostic Laboratories
        12.4.3. Others
    12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Diagnostic Test
        12.6.2. By Sample
        12.6.3. By End-user
        12.6.4. By Country/Sub-region
13. Latin America Lyme Disease Diagnostics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Diagnostic Test, 2017-2031
        13.2.1. Serological Test
            13.2.1.1. ELISA
            13.2.1.2. Western Blot
        13.2.2. Polymerase Chain Reaction (PCR) test
        13.2.3. Others
    13.3. Market Value Forecast, by Sample, 2017-2031
        13.3.1. Blood
        13.3.2. Cerebrospinal Fluid (CSF)
        13.3.3. Others
    13.4. Market Value Forecast, by End-user, 2017-2031
        13.4.1. Hospitals
        13.4.2. Diagnostic Laboratories
        13.4.3. Others
    13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Diagnostic Test
        13.6.2. By Sample
        13.6.3. By End-user
        13.6.4. By Country/Sub-region
14. Middle East & Africa Lyme Disease Diagnostics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Diagnostic Test, 2017-2031
        14.2.1. Serological Test
            14.2.1.1. ELISA
            14.2.1.2. Western Blot
        14.2.2. Polymerase Chain Reaction (PCR) test
        14.2.3. Others
    14.3. Market Value Forecast, by Sample, 2017-2031
        14.3.1. Blood
        14.3.2. Cerebrospinal Fluid (CSF)
        14.3.3. Others
    14.4. Market Value Forecast, by End-user, 2017-2031
        14.4.1. Hospitals
        14.4.2. Diagnostic Laboratories
        14.4.3. Others
    14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Diagnostic Test
        14.6.2. By Sample
        14.6.3. By End-user
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2022)
    15.3. Company Profiles
        15.3.1. LabCorp
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Product Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. Quest Diagnostics
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Product Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. Abbott Laboratories
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Product Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Bio-Rad Laboratories, Inc.
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Product Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview
        15.3.5. bioMérieux SA
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Product Portfolio
            15.3.5.3. Financial Overview
            15.3.5.4. SWOT Analysis
            15.3.5.5. Strategic Overview
        15.3.6. DiaSorin S.p.A.
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Product Portfolio
            15.3.6.3. Financial Overview
            15.3.6.4. SWOT Analysis
            15.3.6.5. Strategic Overview
        15.3.7. T2 Biosystems, Inc.
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Product Portfolio
            15.3.7.3. Financial Overview
            15.3.7.4. SWOT Analysis
            15.3.7.5. Strategic Overview
        15.3.8. F. Hoffmann-La Roche AG
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Product Portfolio
            15.3.8.3. Financial Overview
            15.3.8.4. SWOT Analysis
            15.3.8.5. Strategic Overview
        15.3.9. Meridian Bioscience, Inc.
            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.9.2. Product Portfolio
            15.3.9.3. Financial Overview
            15.3.9.4. SWOT Analysis
            15.3.9.5. Strategic Overview
        15.3.10. Quidel Corporation
            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.10.2. Product Portfolio
            15.3.10.3. Financial Overview
            15.3.10.4. SWOT Analysis
            15.3.10.5. Strategic Overview

 

ページTOPに戻る


 

Summary

Lyme Disease Diagnostics Market – Scope of Report
TMR’s report on the global lyme disease diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global lyme disease diagnostics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lyme disease diagnostics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the lyme disease diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lyme disease diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lyme disease diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lyme disease diagnostics market.

The report delves into the competitive landscape of the global lyme disease diagnostics market. Key players operating in the global lyme disease diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lyme disease diagnostics market profiled in this report.

Key Questions Answered in Global Lyme Disease Diagnostics Market Report
• What is the sales/revenue generated by lyme disease diagnostics across all regions during the forecast period?
• What are the opportunities in the global lyme disease diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Lyme Disease Diagnostics Market – Research Objectives and Research Approach
The comprehensive report on the global lyme disease diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global lyme disease diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lyme disease diagnostics market.



ページTOPに戻る


Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lyme Disease Diagnostics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Lyme Disease Diagnostics Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projection (US$ Mn)
5. Key Insights
    5.1. Innovations in Diagnostic Testing for Lyme disease
    5.2. Incidence and Prevalence of Lyme Disease
    5.3. Regulatory Scenario by Region/Globally
    5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact)
6. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Diagnostic Test
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Diagnostic Test, 2017-2031
        6.3.1. Serological Test
            6.3.1.1. ELISA
            6.3.1.2. Western Blot
        6.3.2. Polymerase Chain Reaction (PCR) test
        6.3.3. Others
    6.4. Market Attractiveness Analysis, by Diagnostic Test
7. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Sample
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Sample, 2017-2031
        7.3.1. Blood
        7.3.2. Cerebrospinal Fluid (CSF)
        7.3.3. Others
    7.4. Market Attractiveness Analysis, by Sample
8. Global Lyme Disease Diagnostics Market Analysis and Forecast, by End-user
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by End-user, 2017-2031
        8.3.1. Hospitals
        8.3.2. Diagnostic Laboratories
        8.3.3. Others
    8.4. Market Attractiveness Analysis, by End-user
9. Global Lyme Disease Diagnostics Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2017-2031
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Lyme Disease Diagnostics Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Diagnostic Test, 2017-2031
        10.2.1. Serological Test
            10.2.1.1. ELISA
            10.2.1.2. Western Blot
        10.2.2. Polymerase Chain Reaction (PCR) test
        10.2.3. Others
    10.3. Market Value Forecast, by Sample, 2017-2031
        10.3.1. Blood
        10.3.2. Cerebrospinal Fluid (CSF)
        10.3.3. Others
    10.4. Market Value Forecast, by End-user, 2017-2031
        10.4.1. Hospitals
        10.4.2. Diagnostic Laboratories
        10.4.3. Others
    10.5. Market Value Forecast, by Country, 2017-2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Diagnostic Test
        10.6.2. By Sample
        10.6.3. By End-user
        10.6.4. By Country
11. Europe Lyme Disease Diagnostics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Diagnostic Test, 2017-2031
        11.2.1. Serological Test
            11.2.1.1. ELISA
            11.2.1.2. Western Blot
        11.2.2. Polymerase Chain Reaction (PCR) test
        11.2.3. Others
    11.3. Market Value Forecast, by Sample, 2017-2031
        11.3.1. Blood
        11.3.2. Cerebrospinal Fluid (CSF)
        11.3.3. Others
    11.4. Market Value Forecast, by End-user, 2017-2031
        11.4.1. Hospitals
        11.4.2. Diagnostic Laboratories
        11.4.3. Others
    11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Diagnostic Test
        11.6.2. By Sample
        11.6.3. By End-user
        11.6.4. By Country/Sub-region
12. Asia Pacific Lyme Disease Diagnostics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Diagnostic Test, 2017-2031
        12.2.1. Serological Test
            12.2.1.1. ELISA
            12.2.1.2. Western Blot
        12.2.2. Polymerase Chain Reaction (PCR) test
        12.2.3. Others
    12.3. Market Value Forecast, by Sample, 2017-2031
        12.3.1. Blood
        12.3.2. Cerebrospinal Fluid (CSF)
        12.3.3. Others
    12.4. Market Value Forecast, by End-user, 2017-2031
        12.4.1. Hospitals
        12.4.2. Diagnostic Laboratories
        12.4.3. Others
    12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Diagnostic Test
        12.6.2. By Sample
        12.6.3. By End-user
        12.6.4. By Country/Sub-region
13. Latin America Lyme Disease Diagnostics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Diagnostic Test, 2017-2031
        13.2.1. Serological Test
            13.2.1.1. ELISA
            13.2.1.2. Western Blot
        13.2.2. Polymerase Chain Reaction (PCR) test
        13.2.3. Others
    13.3. Market Value Forecast, by Sample, 2017-2031
        13.3.1. Blood
        13.3.2. Cerebrospinal Fluid (CSF)
        13.3.3. Others
    13.4. Market Value Forecast, by End-user, 2017-2031
        13.4.1. Hospitals
        13.4.2. Diagnostic Laboratories
        13.4.3. Others
    13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Diagnostic Test
        13.6.2. By Sample
        13.6.3. By End-user
        13.6.4. By Country/Sub-region
14. Middle East & Africa Lyme Disease Diagnostics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Diagnostic Test, 2017-2031
        14.2.1. Serological Test
            14.2.1.1. ELISA
            14.2.1.2. Western Blot
        14.2.2. Polymerase Chain Reaction (PCR) test
        14.2.3. Others
    14.3. Market Value Forecast, by Sample, 2017-2031
        14.3.1. Blood
        14.3.2. Cerebrospinal Fluid (CSF)
        14.3.3. Others
    14.4. Market Value Forecast, by End-user, 2017-2031
        14.4.1. Hospitals
        14.4.2. Diagnostic Laboratories
        14.4.3. Others
    14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Diagnostic Test
        14.6.2. By Sample
        14.6.3. By End-user
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2022)
    15.3. Company Profiles
        15.3.1. LabCorp
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Product Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. Quest Diagnostics
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Product Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. Abbott Laboratories
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Product Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Bio-Rad Laboratories, Inc.
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Product Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview
        15.3.5. bioMérieux SA
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Product Portfolio
            15.3.5.3. Financial Overview
            15.3.5.4. SWOT Analysis
            15.3.5.5. Strategic Overview
        15.3.6. DiaSorin S.p.A.
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Product Portfolio
            15.3.6.3. Financial Overview
            15.3.6.4. SWOT Analysis
            15.3.6.5. Strategic Overview
        15.3.7. T2 Biosystems, Inc.
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Product Portfolio
            15.3.7.3. Financial Overview
            15.3.7.4. SWOT Analysis
            15.3.7.5. Strategic Overview
        15.3.8. F. Hoffmann-La Roche AG
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Product Portfolio
            15.3.8.3. Financial Overview
            15.3.8.4. SWOT Analysis
            15.3.8.5. Strategic Overview
        15.3.9. Meridian Bioscience, Inc.
            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.9.2. Product Portfolio
            15.3.9.3. Financial Overview
            15.3.9.4. SWOT Analysis
            15.3.9.5. Strategic Overview
        15.3.10. Quidel Corporation
            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.10.2. Product Portfolio
            15.3.10.3. Financial Overview
            15.3.10.4. SWOT Analysis
            15.3.10.5. Strategic Overview

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

Transparency Market Research社の医療分野での最新刊レポート


よくあるご質問


Transparency Market Research社はどのような調査会社ですか?


トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/21 10:26

156.13 円

165.08 円

200.38 円

ページTOPに戻る